2-乙酰氨基吡啶-5-硼酸频哪醇酯 | 904326-87-0

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 2-乙酰氨基吡啶-5-硼酸频哪醇酯
• 中文别名: 2-乙酰氨基吡啶-5-硼酸频那醇酯
• 英文名称: N-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl)acetamide
• 英文别名: 2-acetamidopyridine-5-boronic acid pinacol ester；N-[5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl]acetamide
• CAS: 904326-87-0
• 化学式: C₁₃H₁₉BN₂O₃
• mdl: MFCD08690229
• 分子量: 262.116
• InChiKey: YCWPTBAHVWJMEY-UHFFFAOYSA-N

物化性质

• 熔点：
  130-134 °C
• 沸点：
  444.4±30.0 °C(Predicted)
• 密度：
  1.11±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.61
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.538
• 拓扑面积：
  60.4
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S26
• 危险类别码：
  R36/37/38
• WGK Germany：
  3
• 海关编码：
  2934999090
• 危险标志：
  GHS07
• 危险性描述：
  H315,H319,H335
• 危险性防范说明：
  P261,P305 + P351 + P338
• 储存条件：
  存储条件：2-8°C，密封于干燥处。

SDS

---

Section 1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE
Product identifiers
Product name : 2-Acetamidopyridine-5-boronic acid pinacol ester
CAS-No. : 904326-87-0
Relevant identified uses of the substance or mixture and uses advised against
Identified uses : Laboratory chemicals, Manufacture of substances

---

Section 2. HAZARDS IDENTIFICATION
Classification of the substance or mixture
Classification according to Regulation (EC) No 1272/2008 [EU-GHS/CLP]
Skin irritation (Category 2)
Eye irritation (Category 2)
Specific target organ toxicity - single exposure (Category 3)
Classification according to EU Directives 67/548/EEC or 1999/45/EC
Irritating to eyes, respiratory system and skin.
Label elements
Labelling according Regulation (EC) No 1272/2008 [CLP]
Pictogram
Signal word Warning
Hazard statement(s)
H315 Causes skin irritation.
H319 Causes serious eye irritation.
H335 May cause respiratory irritation.
Precautionary statement(s)
P261 Avoid breathing dust/ fume/ gas/ mist/ vapours/ spray.
P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove
contact lenses, if present and easy to do. Continue rinsing.
Supplemental Hazard none
Statements
According to European Directive 67/548/EEC as amended.
Hazard symbol(s)
R-phrase(s)
R36/37/38 Irritating to eyes, respiratory system and skin.
S-phrase(s)
S26 In case of contact with eyes, rinse immediately with plenty of water and
seek medical advice.
Other hazards - none

---

Section 3. COMPOSITION/INFORMATION ON INGREDIENTS
Substances
Synonyms : N-[5-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-2-pyridyl]acetamide
Formula : C13H19BN2O3
Molecular Weight : 262,11 g/mol
Component Concentration
2-Acetamidopyridine-5-boronic acid pinacol ester
CAS-No. 904326-87-0 -

---

Section 4. FIRST AID MEASURES
Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Consult a physician.
In case of eye contact
Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.
Most important symptoms and effects, both acute and delayed
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.
Indication of any immediate medical attention and special treatment needed
no data available

---

Section 5. FIREFIGHTING MEASURES
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Carbon oxides, nitrogen oxides (NOx), Borane/boron oxides
Advice for firefighters
Wear self contained breathing apparatus for fire fighting if necessary.
Further information
no data available

---

Section 6. ACCIDENTAL RELEASE MEASURES
Personal precautions, protective equipment and emergency procedures
Use personal protective equipment. Avoid dust formation. Avoid breathing vapors, mist or gas. Ensure
adequate ventilation. Evacuate personnel to safe areas. Avoid breathing dust.
Environmental precautions
Do not let product enter drains.
Methods and materials for containment and cleaning up
Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed
containers for disposal.
Reference to other sections
For disposal see section 13.

---

Section 7. HANDLING AND STORAGE
Precautions for safe handling
Avoid contact with skin and eyes. Avoid formation of dust and aerosols.
Provide appropriate exhaust ventilation at places where dust is formed.Normal measures for preventive fire
protection.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Specific end uses
no data available

---

Section 8. EXPOSURE CONTROLS/PERSONAL PROTECTION
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and
at the end of workday.
Personal protective equipment
Eye/face protection
Safety glasses with side-shields conforming to EN166 Use equipment for eye protection tested
and approved under appropriate government standards such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
impervious clothing, The type of protective equipment must be selected according to the
concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
For nuisance exposures use type P95 (US) or type P1 (EU EN 143) particle respirator.For higher
level protection use type OV/AG/P99 (US) or type ABEK-P2 (EU EN 143) respirator cartridges.
Use respirators and components tested and approved under appropriate government standards
such as NIOSH (US) or CEN (EU).

---

Section 9. PHYSICAL AND CHEMICAL PROPERTIES
Information on basic physical and chemical properties
a) Appearance Form: solid
b) Odour no data available
c) Odour Threshold no data available
d) pH no data available
e) Melting point/freezing Melting point/range: 130 - 134 °C
point
f) Initial boiling point and no data available
boiling range
g) Flash point no data available
h) Evaporation rate no data available
i) Flammability (solid, gas) no data available
j) Upper/lower no data available
flammability or
explosive limits
k) Vapour pressure no data available
l) Vapour density no data available
m) Relative density no data available
n) Water solubility no data available
o) Partition coefficient: n- no data available
octanol/water
p) Autoignition no data available
temperature
q) Decomposition no data available
temperature
r) Viscosity no data available
s) Explosive properties no data available
t) Oxidizing properties no data available
Other safety information
no data available

---

Section 10. STABILITY AND REACTIVITY
Reactivity
no data available
Chemical stability
no data available
Possibility of hazardous reactions
no data available
Conditions to avoid
no data available
Incompatible materials
Strong oxidizing agents
Hazardous decomposition products
Other decomposition products - no data available

---

Section 11. TOXICOLOGICAL INFORMATION
Information on toxicological effects
Acute toxicity
no data available
Skin corrosion/irritation
no data available
Serious eye damage/eye irritation
no data available
Respiratory or skin sensitization
no data available
Germ cell mutagenicity
no data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
no data available
Specific target organ toxicity - single exposure
Inhalation - May cause respiratory irritation.
Specific target organ toxicity - repeated exposure
no data available
Aspiration hazard
no data available
Potential health effects
Inhalation May be harmful if inhaled. Causes respiratory tract irritation.
Ingestion May be harmful if swallowed.
Skin May be harmful if absorbed through skin. Causes skin irritation.
Eyes Causes serious eye irritation.
Signs and Symptoms of Exposure
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.
Additional Information
RTECS: Not available

---

Section 12. ECOLOGICAL INFORMATION
Toxicity
no data available
Persistence and degradability
no data available
Bioaccumulative potential
no data available
Mobility in soil
no data available
Results of PBT and vPvB assessment
no data available
Other adverse effects
no data available

---

Section 13. DISPOSAL CONSIDERATIONS
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company. Contact a licensed
professional waste disposal service to dispose of this material. Dissolve or mix the material with a
combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber.
Contaminated packaging
Dispose of as unused product.

---

Section 14. TRANSPORT INFORMATION
UN number
ADR/RID: - IMDG: - IATA: -
UN proper shipping name
ADR/RID: Not dangerous goods
IMDG: Not dangerous goods
IATA: Not dangerous goods
Transport hazard class(es)
ADR/RID: - IMDG: - IATA: -
Packaging group
ADR/RID: - IMDG: - IATA: -
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
no data available

---

---

SECTION 15 - REGULATORY INFORMATION
N/A

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-乙酰氨基吡啶-5-硼酸频哪醇酯 、 [11C]二氧化碳 在 potassium fluoride 、 copper(l) iodide 、 四甲基乙二胺 、 4,7,13,16,21,24-六氧-1,10-二氮双环[8.8.8]二十六烷 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 0.08h， 以18%的产率得到
  参考文献：
  名称：

  CuI催化的硼酸酯的 11C 羧化：快速方便地进入 11C 标记的羧酸、酯和酰胺

  摘要：

  快速直接：硼酸酯与11 CO 2的羧化反应提供了 [ 11 C] 羧酸，可方便地进入 [ 11 C] 酯和 [ 11 C] 酰胺（见方案）。这种硼酸盐的转化对不同的官能团（例如卤素、硝基或羰基）具有耐受性。

  DOI：

  10.1002/anie.201107263
• 作为产物：
  描述：

  2-氨基吡啶-5-硼酸,频哪醇酯 在 2-二甲氨基吡啶 、 乙酸酐 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 以63.1%的产率得到2-乙酰氨基吡啶-5-硼酸频哪醇酯
  参考文献：
  名称：

  Pyridonaphthyridine PI3K/MTOR Dual Inhibitors and Preparation and Use Thereof

  摘要：

  本发明涉及一种由通式（I）表示的吡啶萘啉化合物，其具有双重PI3K和mTOR抑制作用，以及其药学上可接受的盐、立体异构体和氘代物，其中R1、R2、R3、R4、R5、R6、R7和X如规范中所定义；本发明还涉及一种制备所述化合物的方法，含有所述化合物的药物组合物和药物配方，以及所述化合物在治疗和/或预防增殖性疾病以及制造用于治疗和/或预防增殖性疾病的药物的用途。

  公开号：

  US20140093505A1

文献信息

• [EN] INHIBITORS OF WDR5 PROTEIN-PROTEIN BINDING<br/>[FR] INHIBITEURS DE LA LIAISON PROTÉINE WDR5-PROTÉINE
  申请人：ONTARIO INST FOR CANCER RES (OICR)

  公开号：WO2017147700A1

  公开（公告）日：2017-09-08

  The present application is directed to compounds of Formula I: compounds comprising these compounds and their uses, for example as medicaments for the treatment of diseases, disorders or conditions mediated or treatable by inhibition of binding between WDR5 protein and its binding partners.

  本申请涉及到Formula I的化合物：包括这些化合物的化合物及其用途，例如作为治疗由于抑制WDR5蛋白与其结合伙伴之间结合而介导或可治疗的疾病、疾病或症状的药物。
• In vitro evaluation of imidazo[4,5 -c ]quinolin-2-ones as gametocytocidal antimalarial agents
  作者：Paresma R. Patel、Wei Sun、Myunghoon Kim、Xiuli Huang、Philip E. Sanderson、Takeshi Q. Tanaka、John C. McKew、Anton Simeonov、Kim C. Williamson、Wei Zheng、Wenwei Huang

  DOI：10.1016/j.bmcl.2016.04.045

  日期：2016.6

  Novel imidazo[4,5-c]quinolin-2-ones were synthesized and evaluated in asexual blood stage and late stage gametocyte assays of Plasmodium falciparum, a major causative agent of malaria. The design of these compounds is based on a recently identified lead compound from a high throughput screen. A concise synthesis was developed that allowed for generation of analogues with substitution around both the

  合成了新型咪唑并[4,5-c]喹啉-2-酮，并在疟疾的主要病原体恶性疟原虫的无性血液阶段和晚期配子细胞测定中进行了评估。这些化合物的设计基于最近从高通量筛选中鉴定出的先导化合物。开发了一种简明的合成方法，该方法可生成在喹啉和咪唑烷酮环上均被取代的类似物。通过结构-活性关系研究，鉴定了许多有效的化合物，它们对无性和有性阶段均具有优异的抗疟活性，并且在哺乳动物细胞中具有最小的细胞毒性。这是第一封描述咪唑并[4,5-c]喹啉-2-酮（一种新的用于治疗和预防疟疾的先导系列产品）的SAR和杀真菌活性的第一封信。
• [EN] TANK-BINDING KINASE INHIBITOR COMPOUNDS<br/>[FR] COMPOSÉS INHIBITEURS DE KINASES SE LIANT À TANK
  申请人：GILEAD SCIENCES INC

  公开号：WO2015187684A1

  公开（公告）日：2015-12-10

  Compounds having the following formula (I) and methods of their use and preparation are disclosed:

  揭示了具有以下化学式（I）的化合物及其使用和制备方法。
• Synthesis of New Quinolinequinone Derivatives and Preliminary Exploration of their Cytotoxic Properties
  作者：Charles M. Keyari、Alison K. Kearns、Nathan S. Duncan、Emily A. Eickholt、Geoffrey Abbott、Howard D. Beall、Philippe Diaz

  DOI：10.1021/jm301689x

  日期：2013.5.23

  A series of 7-amino- and 7-acetamidoquinoline-5,8-diones with aryl substituents at the 2-position were synthesized, characterized, and evaluated as potential NAD(P)H:quinone oxidoreductase (NQO1) -directed antitumor agents. The synthesis of lavendamycin analogues is illustrated. Metabolism studies demonstrated that 7-amino analogues were generally better substrates for NQO1 than 7-amido analogues,

  合成、表征和评估了一系列在 2 位具有芳基取代基的 7-氨基和 7-乙酰氨基喹啉-5,8-二酮，并将其评估为潜在的 NAD(P)H: 醌氧化还原酶 (NQO1) 定向抗肿瘤剂。说明了拉文霉素类似物的合成。代谢研究表明，7-氨基类似物通常是 NQO1 比 7-酰胺类似物更好的底物，在 C-2 位置具有较小杂芳族取代基的化合物也是如此。令人惊讶的是，只有两种化合物，7-acetamido-2-(8'-quinolinyl)quinoline-5,8-dione ( 11 ) 和 7-amino-2-(2-pyridinyl)quinoline-5,8-dione ( 23))，与 NQO1 缺失的 MDA468-WT 细胞相比，对表达 NQO1 的 MDA468-NQ16 乳腺癌细胞显示出选择性细胞毒性。对于所有其他化合物，NQO1 可防止喹啉-5,8-二酮细胞毒性。化合物22对表达或不表达 NQO1
• [EN] INDAZOLES<br/>[FR] INDAZOLES
  申请人：GLAXOSMITHKLINE LLC

  公开号：WO2011140325A1

  公开（公告）日：2011-11-10

  Herein are disclosed indazoles of formula (I) where the various groups are defined herein, and which are useful for treating cancer.

  以下披露了式(I)的吲唑化合物，其中各种基团在此处定义，并且这些化合物对治疗癌症有用。